Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence

Cancer Treatment Reviews

Volumn 22, Issue 2, 1996, Pages 105-118

  Middleman, Matthew N ^a   Lush, Richard M ^a   Sartor, Oliver ^a   Reed, Eddie ^a   Figg, William D ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Clinical Pharmacology Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ESTROGEN; FLUTAMIDE; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN;

DRUG EFFICACY; DRUG MECHANISM; HORMONAL THERAPY; HUMAN; MALE; METASTASIS; MOLECULAR BIOLOGY; PROSTATE CANCER; REVIEW;

EID: 0030018197     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(96)90030-4     Document Type: Article

References (61)

1. Wingo, P. A., Tong, T. & Bolden, S. (1995) Cancer statistics. CA Cancer J. Clin. 45: 8-30.
2. Smith, J. A. Jr., Hernandez, A. D., Wittwer, C. J. et al. (1991) Long term follow-up after radical prostatectomy. Urol. Clin. N. Am. 18: 473-480.
3. Wasson, J. H., Custman, C. C., Bruskewitz, R. C., Littenberg, B., Mulley, A. G. Jr. & Wennberg, J.E. (1993) A structured literature review of treatment for localized prostate cancer. Prostate disease patient outcome research team. Arch. Fam. Med. 5: 487-493.
4. Stanford, J. L., Wicklund, K. G., Blumenstein, B. A. & Brawer, M. K. (1995) The changing epidemiology of prostate cancer in the Seattle/Puget Sound region, 1974-1993. J. Urol. 153: 1102.
5. Slawin, K. M., Ohori, M., Dillioglugil, O. & Scardino, P. T. (1995) Screening for prostate cancer: An analysis of the early experience. Cancer J. Clin. 45: 134-147.
6. Crawford, E. D., Eisenberger, M. A., McCleod, D. G. et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med 321: 419-424.
7. Denis, L. J., Carnelro de Moura, J. L., Bono, A. et al. (1993) Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTIC trial. Urology 42: 119-130.
8. Huggins, C. & Hodges, C. V. (1941) Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297.
9. Byar, D. P. (1973) The Veterans Administration Cooperative Urologic Research Group's studies of cancer of the prostate. Cancer 32: 1126-1130.
10. Bailar, J. C. & Byar, D. P. (1970) The Veterans Administration Cooperative Urologic Research Group: Estrogen treatment for cancer of the prostate: early results with 3 doses of diethylstilbestrol and placebo. Cancer 26: 257-261.
11. Blackard, C. E., Doe, R. P., Mellinger, G. T. & Byar, D. P. (1970) Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 26: 249-256.
12. The Leuprolide Study Group (1984) Leuprolide versus diethylstil-bestrol for metastatic prostate cancer. N. Engl. J. Med. 311: 1281-1286.
13. Kuhn, J. M., Billebaud, T., Navratil, H. et al. (1989) Prevention of the transient adverse effects of gonadotropin-releasing hormone analogue (Buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl. J. Med. 321: 413.
14. Labrie, F., Belanger, A., Simard, J., Labrie, C. & Dupont, A. (1993) Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 71 (Suppl.): 1059-1067.
15. Labrie, F., Dupont, A., Belanger, M. et al. (1985) Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J. Steroid Biochem. 23: 833-841.
16. Crawford, E. D., Blumenstein, B. A., Goodman, P. J. et al. (1990) Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66: 1039-1044.
17. Prostate Cancer Trialists' Collaborative Group (1995) Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346: 265-269.
18. Crawford, E. D., Hussain, M., DeAntoni, E. P. et al. (1995) Southwestern Oncology Group strategies in prostate carcinoma. Sem. Surg. Oncol. 11: 60-64.
19. Poyet, P. & Labrie, F. (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol. Cell Endocr. 42: 283.
20. Labrie, C., Cusan, L., Plante, M., Lapointe, S. & Labrie, F. (1987) Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem. 28: 379.
21. Schellhammer, P., Sharifi, R., Block, N. et al. (1995) A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745-752.
22. Crawford, E. D. (1992) Challenges in the management of prostate cancer. Br. J. Urology 70: 33-38.
23. Kelly, W. K. & Scher, H. I. (1993) Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol. 149: 607-609.
24. Scher, H. I. & Kelly, W. K. (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 11: 1566-1572.
25. Figg, W. D., Sartor, O., Cooper, M. et al. (1995) Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am. J. Med. 98: 412-414.
26. Srinivas, S. & Small, E. J. (1995) The antiandrogen withdrawal syndrome: experience in a large cohort of unselected advanced prostate cancer patients. Proc. Amer. Urol. Assoc. 153: 448A.
27. Sartor, O., Cooper, M., Weinberger, M. et al. (1994) Surprising activity of flutamide withdrawal, when combined with aminoglutethimide in treatment of "hormone-refractory" prostate cancer. J. Natl. Cancer Inst. 86: 222-227.
28. Dupont, A., Gomez, J. L., Cusan, L., Koutsilieris, M. & Labrie, F. (1993) Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol. 150: 908-913.
29. Figg, W. D., Dawson, N. A., Middleman, M. N. et al. (1995) Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with "hormone refractory" prostate cancer. Acta Oncol. (in press).
30. Small, E. J. & Carroll, P. R. (1994) Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43: 408-410.
31. Nieh, P. T. (1995) Withdrawal phenomenon with the antiandrogen casodex. J. Urol. 153: 1070-1073.
32. Kyprianou, N. & Isaacs, J. T. (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552-562.
33. 2+ dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 13: 103-118.
34. Martikainen, P. & Isaacs, J. T. (1989) Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 17: 175-188.
35. English, H. F., Kyprianou, N., Tucker, R. W. & Isaacs, J. T. (1989) Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15: 233-251.
36. Kerr, J. F. R. & Searle, J. (1980) Apoptosis: its nature and kinetic role. In: Meyn, R. E. & Withers, H. R., eds. Radiation Biology in Cancer Research. New York: Raven Press, pp. 367-384.
37. Leger, J. G., Monpetit, M. L. & Tenniswood, M. P. (1987) Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate. Biochem. Biophys. Res. Comm. 147: 196.
38. Buttyan, R., Olsson, C. A., Pintar, J. et al. (1989) Introduction of the TRPM-2 gene in cells undergoing programmed death. Mol. Cell. Biol. 9: 3473.
39. Kyprianou, N. & Isaacs, J. T. (1989) Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol. Endocrinol. 3: 1515.
40. Rundlett, S. E., Wu, X. P. & Miesfeld, R. L. (1990) Functional characterization of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol. Endocrinol. 4: 708-714.
41. Allan, G. F., Tsai, S. Y., O'Malley, B. W. & Tsai, J. M. (1991) Steroid hormone receptors and in vitro transcription. Bioassays 13: 73-78.
42. Beato, M. (1989) Gene regulation by steroid hormones. Cell 56: 335-344.
43. Kemppainen, J. A., Lane, M. V., Sar, M. & Wilson, E. M. (1992) Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. J. Biol. Chem. 267: 968-974.
44. Zhou, Z., Lane, M. V., Kemppainen, J. A., French, F. S. & Wilson, E. M. (1995) Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Molecular Endo. 9: 208-218.
45. Zhou, Z., Lane, M. V., Kemppainen, J. A. & Wilson, E. M. (1995) Identification of three proline-directed phosphorylation sites in the human androgen receptor. Molecular Endo. 9: 605-615.
46. Liu, X., Witey, H. S. & Meikle, A. W. (1993) Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-α (TGF-α) and epidermal growth factor (EGF)/TGF-α receptor. J. Clin. Endo. Metab. 77: 1472-1478.
47. Figg, W. D., McCall, N. A., Reed, E. & Sartor, O. (1995) The in vitro response of four antisteroid receptor agents on the hormone-responsive prostate cancer cell line LNCaP. Oncol. Reports 2: 1-4.
48. Wilding, G., Chen, M. & Gelman, E. P. (1989) Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14: 103-115.
49. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M. et al. (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem. Biophys. Res. Commun. 173: 534-540.
50. Berrevoets, C. A., Veldscholte, J. & Mulder, E. (1993) Effects of antiandrogens on transformation activation of wild-type and mutated (LNCaP) androgen receptors. J. Steroid Biochem. Molec. Biol. 46: 731-736.
51. Culig, Z., Hobisch, A., Cronauer, M. V. et al. (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 12: 1541-1550.
52. Suzuki, H., Sato, N., Watabe, Y., Masai, M., Seino, S. & Shimazaki, J. (1993) Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Molec. Biol. 46: 759-765.
53. Gaddipati, J. P., McLeod, D. G., Heidenberg, H. B. et al. (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54: 2861-2864.
54. Taplin, M. E., Bubley, G. J., Shuster, T. D. et al. (1995) Androgen receptor mutations in metastatic androgen independent prostate cancer. N. Engl. J. Med. 332: 1393-1398.
55. Tilley, W. D., Buchanan, G. Hickey, T. E. & Horsfall, D. J. (1995) Detection of androgen receptor mutations in human prostate cancers by immunohistochemistry and SSCP. Proc. Am. Assoc. Cancer Res. 36: 266.
56. Scher, H., Hardy, D. O., Bogenreider, T. et al. (1995) Androgen receptor CAG repeat length polymorphisms in patients with prostatic cancer (PC): association with sensitivity to androgen ablation. Proc. Am. Soc. Clin. Oncol. 14: 232.
57. 24→18) in the androgen receptor gene in human prostate cancer. Biochem. Biophys. Res. Commun. 198: 74-80.
58. Courey, A. J., Holtzman, D. A., Jackson, S. P. et al. (1989) Synergistic activation by the glutamine-rich domains of human transcription factor Sp1. Cell 59: 827-836.
59. Bowden, C. J., Figg, W. D., Dawson, N. A. et al. (1995) A phase I/II study of continuous infusion suramin in patients with hormone refractory prostate cancer: toxicity and response rate. Cancer Chemother. Pharmaco. (in press).
60. Haynes, R. C. (1990) Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Gillman, A. G., Rail, T. W., Nies, A. S., Taylor, P., eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: Pergamon Press, pp. 1458-1459.
61. Liebertz, C., Kelly, W. K., Theodoulou, M. et al. (1995) High dose casodex for prostate cancer (PC): PSA declines in patients (pts) with flutamide withdrawal responses. Proc. Am. Soc. Clin. Oncol. 14: 232.